Here are 1-3 brief analogies for Tilray Brands (TLRY):

• Imagine a company like Constellation Brands (known for beer, wine, and spirits), but with a massive additional focus on cultivating, producing, and distributing cannabis products globally, along with other wellness items.
• It's similar to a large diversified beverage company like Diageo, which owns many alcohol brands, but Tilray also operates a global business in medical and adult-use cannabis, plus other wellness products.

• Medical Cannabis Products: The company provides GMP-certified flowers, oils, vapes, edibles, and topicals for medical use.
• Adult-Use Cannabis Products: Tilray Brands offers various cannabis products designed for recreational adult consumption.
• Beverage Alcohol Products: The company produces and distributes a range of alcoholic beverages.
• Wellness Products: This category includes pharmaceutical products, hemp-based food, and other general wellness items.
• Distribution Services: Tilray Brands operates a distribution business for various pharmaceutical and wellness products.

Tilray Brands Inc. (TLRY) primarily sells its products to other companies and institutions, which then distribute or sell to end-consumers. While Tilray also serves individual patients directly through its medical platform, the bulk of its sales channels are business-to-business (B2B).

For its Cannabis Business segment, particularly for adult-use cannabis in Canada, Tilray's major customers are the provincial and territorial government-controlled distributors. These entities act as the sole wholesalers or distributors within their respective provinces. Examples of these major customer entities include:

• Ontario Cannabis Store (OCS): The Crown corporation that is the sole legal wholesale distributor for recreational cannabis in Ontario, Canada.
• Société québécoise du cannabis (SQDC): A subsidiary of the Société des alcools du Québec, it is the sole legal retailer and distributor of recreational cannabis in Quebec, Canada.
• British Columbia Liquor Distribution Branch (BCLDB - Cannabis): The provincial Crown corporation responsible for the wholesale distribution of recreational cannabis in British Columbia, Canada.

For its other business segments, including medical cannabis (globally), beverage alcohol, and wellness products, Tilray sells to a diverse range of B2B customers such as pharmacies, clinics, wholesalers, various retailers (e.g., liquor stores, grocery chains, health food stores), hospitals, and other governmental entities for research or institutional supply. Specific major customer companies in these diverse sectors are not typically disclosed publicly by Tilray due to the competitive nature of its markets.

None of the listed governmental customers (OCS, SQDC, BCLDB) are publicly traded companies with stock symbols.

Irwin D. Simon, Chairman and Chief Executive Officer

Irwin D. Simon is the Chairman and Chief Executive Officer of Tilray Brands, Inc.. He is recognized as a forefather of the organic and natural products industry, having founded The Hain Celestial Group, Inc. (NASDAQ: HAIN) in 1993, a leading organic and natural products company that he led as Founder, President, Chief Executive Officer, and Chairman for 30 years, growing it to $3.5 billion in operations across North America, Europe, Asia, and the Middle East. Before Tilray, Mr. Simon transformed Aphria Inc. into a profitable global cannabis company and subsequently oversaw its merger with Tilray, creating one of the largest global cannabis groups.

Carl Merton, Chief Financial Officer

Carl Merton is the Chief Financial Officer of Tilray Brands, Inc.. He possesses over 25 years of financial and business experience, including nearly 12 years combined with Ernst & Young LLP and KPMG LLP. Mr. Merton joined Tilray from Aphria Inc., where he served as Chief Financial Officer and was instrumental in transforming the company into a global cannabis leader. Prior to his role at Aphria, he held positions as Vice-President, Special Projects at Atlas Tube Canada ULC and Chief Financial Officer of Reko International Group Inc. (TSXV: REK).

Denise Faltischek, Chief Strategy Officer and Head of International

Denise Faltischek serves as the Chief Strategy Officer and Head of International Business at Tilray Brands, Inc.. Before joining Tilray, she was the Chief Strategy Officer at Aphria Inc., where she played a pivotal role in establishing Aphria as a global cannabis leader. Ms. Faltischek also served as Executive Vice President and Chief Strategy Officer at The Hain Celestial Group, Inc. (NASDAQ: HAIN), where she led the successful completion of more than 50 acquisitions.

Jim Meiers, Chief Operations Officer

Jim Meiers was appointed Chief Operations Officer of Tilray Brands, Inc. in October 2021.

Mitchell S. Gendel, Global General Counsel and Corporate Secretary

Mitchell S. Gendel joined Tilray Brands in July 2021 as Global General Counsel and Corporate Secretary.

Key Risks to Tilray Brands (TLRY)

1. Regulatory Uncertainty and Challenges: Tilray operates within the highly regulated cannabis industry, facing significant risks from evolving and inconsistent cannabis laws and regulations across different jurisdictions (federal, state, and international). Delays or unfavorable outcomes in potential federal reclassification of cannabis in the U.S., varying state-level regulations, and restrictions in international markets can severely impact the company's ability to expand, operate efficiently, and achieve profitability.
2. Persistent Profitability Issues and Financial Strain: Tilray has consistently struggled with achieving and maintaining sustainable profitability. The company has reported negative operating margins, significant net losses, and declining revenue in its core cannabis business. These financial pressures are exacerbated by challenges in cost management, excise taxes, pricing competition, and a substantial debt load, which together create ongoing concerns about the company's financial health and long-term viability.
3. Shareholder Dilution and Stock Performance Volatility: Tilray has a history of funding acquisitions through stock issuance, leading to substantial dilution for existing shareholders. The company's stock has experienced significant declines, is subject to high volatility, and has faced the risk of delisting from NASDAQ due to its low share price, impacting shareholder value and investor confidence.

The clear emerging threat to Tilray Brands (TLRY) is the evolving regulatory landscape of cannabis in the United States, particularly concerning potential federal reform and the competitive advantage held by established U.S. Multi-State Operators (MSOs).

As more U.S. states legalize cannabis and discussions around federal reform intensify (e.g., descheduling, SAFE Banking Act, or state-level protections), there is a significant risk that Tilray and other Canadian Licensed Producers (LPs) will face substantial competitive disadvantages if the U.S. market opens up in a way that primarily benefits existing domestic operators. U.S. MSOs have been rapidly expanding, consolidating, building brands, and establishing cultivation and distribution networks within state-legal markets. Should federal barriers to interstate commerce be lifted, particularly if accompanied by initial restrictions or hurdles for non-U.S. entities, these domestic MSOs could capture a dominant share of the vast U.S. cannabis market before Tilray can effectively enter or scale its operations there. This creates a scenario where Tilray could struggle to compete against entrenched, well-capitalized U.S. players who have had a significant head start and regulatory tailwind in their home market, akin to a market structure shift.

Tilray Brands Inc. operates within several addressable markets for its diverse product and service offerings. The estimated market sizes for its main product categories across relevant regions are as follows:

Cannabis Business (Medical and Adult-Use Cannabis Products)

• Global Legal Cannabis Market: The global legal cannabis market was estimated at approximately $33.8 billion in 2024 and is projected to reach $110.1 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 21.8% from 2024 to 2030. Another estimate places the market at $69.78 billion in 2024, with a projection to reach $216.76 billion by 2033 at a CAGR of 13.49% from 2025 to 2033.
• Global Medical Cannabis Market: This segment was estimated at $14.34 billion in 2024 and is anticipated to reach around $52.23 billion by 2034, with a CAGR of 13.8% from 2025 to 2034. Another valuation for the global medical cannabis market in 2024 was $25.86 billion, with expectations to reach $133.73 billion by 2032 at a CAGR of 22.8% (2025-2032).
• U.S. Cannabis Market (Legal Adult-Use and Medical): The U.S. cannabis market size was estimated at $38.50 billion in 2024 and is expected to reach $44.30 billion in 2025. Projections indicate it could reach $76.39 billion by 2030, with a CAGR of 11.51% from 2025 to 2030. Legal sales in the U.S. for both adult-use and medical cannabis totaled $30.1 billion in 2024. North America, overall, accounted for over 40% of the global cannabis market revenue in 2024, translating to approximately $23.4458 billion.
• Canada Legal Cannabis Market: The Canadian legal cannabis market was valued at $3.25 billion in 2024 and is projected to reach $5.79 billion by 2030, demonstrating a CAGR of 12.00%. Adult-use cannabis sales in Canada reached C$5.5 billion (approximately $4.05 billion USD) for the fiscal year ending March 31, 2025. Household spending on medical cannabis in Canada for 2024 was $453 million.
• Europe Cannabis Market (Legal Medical and Adult-Use): The European medical cannabis market size in 2024 is estimated at €779 million (approximately $847 million USD). The adult-use cannabis market size in Europe for 2024 is approximately €104 million (approximately $113 million USD). The overall legal cannabis market in Europe more than doubled from 2023 to 2024, reaching over €1 billion (approximately $1.08 billion USD).

Beverage Alcohol Business

• Global Alcoholic Beverages Market: The global alcoholic beverages market was valued at approximately $1,855.75 billion in 2024 and is expected to grow to $2,883.82 billion by 2033, with a CAGR of 5.02% during the period of 2025-2033. Another source estimated the market at $2,319.87 billion in 2024, projected to grow to $3,002.33 billion by 2035 with a CAGR of 2.37% from 2025 to 2035.
• Global Cannabis Beverage Market: This niche market is estimated to be valued at $251.7 million in 2025 and is expected to reach $1,054.4 million by 2032.

Wellness Business (Hemp-Based Food and Other Wellness Products)

• Global Hemp-Based Foods Market: The global hemp-based foods market size was valued at $7.07 billion in 2024 and is projected to reach $15.60 billion by 2032, growing at a CAGR of 10.41% from 2025 to 2032. Another report indicates a market size of $1.42 billion in 2023, anticipated to exceed $4.87 billion by 2033, with a CAGR of 13.12% from 2023 to 2033. North America is a dominant region in this market.
• Global CBD for Health and Wellness Market: The global CBD for Health and Wellness market was valued at $6.407 billion in 2024. It is projected to grow from $6.744 billion in 2025 to $9.123 billion by 2032, at a CAGR of 5.3%. The broader global CBD market was valued at approximately $9.8 billion in 2024 and is expected to reach $23-25 billion by 2030, with a CAGR of 15.2% from 2025 to 2030. Hemp-derived CBD accounted for around 57.2% of total CBD sales in 2024, reaching $5.6 billion. North America represents the largest regional market for CBD, with an estimated value of $7.9 billion in 2024.

Tilray Brands (TLRY) is expected to drive future revenue growth over the next 2-3 years through several key initiatives across its diversified business segments:

1. International Cannabis Market Expansion: Tilray Brands is focusing on expanding its global cannabis footprint, particularly in Europe. The company plans to triple its medical cannabis distribution presence in Germany in fiscal year 2026. This strategy is evidenced by a 36% year-over-year increase in international cannabis revenue in Q2 FY2026.
2. Growth of European Pharmaceutical Distribution Business (Tilray Pharma): The Tilray Pharma segment achieved record revenue in Q2 FY2026, with a 26% year-over-year increase. This growth is attributed to competitive pricing, portfolio optimization, and an increased focus on medical device sales, with plans for continued expansion of its pharmacy network in Germany.
3. Expansion and Product Innovation in the U.S. Beverage Alcohol Market: Tilray Brands has aggressively expanded into the U.S. beverage alcohol sector through strategic acquisitions, establishing itself as the fifth-largest craft brewer in the nation. The company is also launching new hemp-derived Delta-9 THC beverages and is focused on expanding product distribution to additional states.
4. Development of High-Margin, Non-End-User Revenue Streams: Tilray is shifting its business strategy to include intellectual property (IP) licensing and manufacturing partnerships, moving beyond traditional cultivation and retail distribution. This approach aims to monetize its research and development capabilities and scale in product development, especially in the wellness and pharmaceutical segments, with a projected revenue of $1.2 billion for 2027.
5. New Product Development and Value-Added Innovation in the Wellness Business: The company is strategically focused on value-added innovation within its wellness segment, including high-protein super seeds, and "better for you" breakfast products and snacking options.

Share Repurchases

• Tilray Brands has not engaged in significant share repurchases, with multiple sources indicating a negative share buyback ratio or zero dollar amount for buybacks, suggesting an increase in shares outstanding rather than a reduction.
• As of March 9, 2026, Tilray Brands' shares buyback ratio was -25.54%.

Share Issuance

• Tilray Brands' shares outstanding have significantly increased, growing from 24.34 million in 2020 to 110.34 million at the end of 2025.
• This increase, over 300% in the past five years, is primarily attributed to acquisitions funded by stock, which has resulted in dilution for existing shareholders.
• In May 2024, Tilray announced an "at-the-market" equity program to potentially offer and sell up to $250 million of its common stock, with proceeds intended for strategic acquisitions and investments.
• The company executed a 1-for-10 reverse stock split, aimed at aligning its share count with similar-sized companies and enhancing its attractiveness to institutional investors.

Outbound Investments

• Tilray has actively pursued acquisitions, particularly in the beverage alcohol sector, as part of its diversification strategy. Notable acquisitions include SweetWater Brewing Co. (approximately $300 million by Aphria before merging with Tilray in late 2020), Breckenridge Distillery ($102.9 million in December 2021), Alpine Beer Co. and Green Flash Brewing Co. ($5.1 million in late 2021), Montauk Brewing (November 2022), and eight beer and beverage brands from Anheuser-Busch for $85 million in August 2023 (including Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy), which made Tilray the fifth-largest craft beer brewer in the U.S..
• In April 2023, Tilray agreed to acquire Hexo Corp. for approximately US$56 million.
• As of March 2026, Tilray completed the acquisition of certain BrewDog assets for £33 million (approximately $44.5 million), including the global brand, intellectual property, UK brewing operations, and eleven brewpubs.

Capital Expenditures

• Tilray Brands reported capital expenditures of -$39.96 million in the last 12 months.
• In Q2 2025, the company invested $6.3 million in capital expenditures for long-term assets and infrastructure.
• These expenditures are focused on improving operational efficiencies and expanding its global supply chain and cannabis cultivation footprint, including the completion of Phase I of its cannabis supply chain growth plan in early 2025, which increased cultivation capacity to approximately 247 metric tonnes, and the commencement of Phase II, which involves planting an outdoor cultivation site in Cayuga.